Xponance Inc. Sells 948 Shares of DexCom, Inc. (NASDAQ:DXCM)

Xponance Inc. trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,199 shares of the medical device company’s stock after selling 948 shares during the quarter. Xponance Inc.’s holdings in DexCom were worth $6,937,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Jennison Associates LLC boosted its position in shares of DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after purchasing an additional 6,544,102 shares in the last quarter. Congress Asset Management Co. boosted its position in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD bought a new position in shares of DexCom during the fourth quarter worth $96,507,000. Westfield Capital Management Co. LP boosted its position in shares of DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its position in shares of DexCom by 182.7% during the third quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after purchasing an additional 739,000 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock worth $8,044,178 in the last ninety days. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of a number of recent analyst reports. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Canaccord Genuity Group boosted their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $99.82.

DexCom Stock Up 3.8 %

DexCom stock opened at $73.38 on Thursday. The firm has a market capitalization of $28.67 billion, a PE ratio of 51.31, a P/E/G ratio of 2.30 and a beta of 1.28. The company’s 50-day moving average is $83.51 and its 200-day moving average is $76.93. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.